Jun 15, 2026 07:02AM
Jun 2, 2026 07:02AM
Jun 2, 2026 07:02AM
May 4, 2026 07:01AM
May 4, 2026 07:01AM
Apr 20, 2026 07:01AM
Apr 20, 2026 07:01AM Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Apr 1, 2026 07:03AM
Apr 1, 2026 07:01AM
Nov 20, 2025 04:01PM
Nov 20, 2025 04:01PM
Jul 31, 2025 07:01AM
Jul 31, 2025 07:01AM
May 20, 2025 07:07AM Pasithea Therapeutics (KTTA) Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
May 20, 2025 07:01AM
May 14, 2025 07:02AM
Sep 3, 2024 08:02AM
May 28, 2024 06:59AM
May 28, 2024 06:59AM
Apr 29, 2024 07:59AM
Apr 24, 2024 07:59AM Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Feb 13, 2024 07:59AM
Jan 8, 2024 07:59AM
Jan 8, 2024 07:59AM
Jan 2, 2024 08:35AM
Jan 2, 2024 08:35AM
Dec 11, 2023 08:01AM
Nov 29, 2023 07:59AM Pasithea Therapeutics (KTTA) Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
Nov 29, 2023 07:59AM
Nov 9, 2023 07:59AM
Nov 9, 2023 07:59AM
Jun 29, 2023 08:29AM
Jun 1, 2023 07:57AM
Jan 18, 2023 08:00AM
Dec 6, 2022 08:00AM Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference
Oct 12, 2022 08:03AM
Oct 12, 2022 08:00AM
Jul 14, 2022 08:03AM
Jul 14, 2022 08:00AM
Jun 22, 2022 08:04AM
Jun 22, 2022 08:00AM
Feb 24, 2022 08:00AM Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
Jan 26, 2022 08:00AM
Dec 21, 2021 08:00AM
Nov 17, 2021 08:04AM
Nov 17, 2021 08:00AM
Nov 11, 2021 08:00AM
Oct 27, 2021 07:45AM
Oct 14, 2021 07:45AM Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom

326,087 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All